Verition Fund Management
MDGL icon

Verition Fund Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Verition Fund Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.02M Buy
+7,490
New +$3.84M 0.02% 754
2026
Q1 		– Sell
-8,893
Closed -$5.18M – 3052
2025
Q4 		$5.18M Buy
8,893
+3,263
+58% +$1.67M 0.02% 849
2025
Q3 		$2.58M Buy
5,630
+1,310
+30% +$489K 0.01% 1765
2025
Q2 		$1.31M Buy
4,320
+296
+7% +$88.2K 0.01% 2269
2025
Q1 		$1.33M Buy
4,024
+24
+0.6% +$7.89K 0.01% 1891
2024
Q4 		$1.23M Hold
4,000
– – ﹤0.01% 1910
2024
Q3 		$849K Hold
4,000
– – ﹤0.01% 1998
2024
Q2 		$1.12M Hold
4,000
– – 0.01% 1604
2024
Q1 		$1.07M Sell
4,000
-29
-0.7% -$6.83K 0.01% 1585
2023
Q4 		$932K Buy
4,029
+29
+0.7% +$5.08K 0.01% 1213
2023
Q3 		$584K Sell
4,000
-1,302
-25% -$245K 0.01% 1345
2023
Q2 		$1.22M Buy
5,302
+325
+7% +$88K 0.02% 858
2023
Q1 		$1.21M Buy
4,977
+2,798
+128% +$762K 0.02% 878
2022
Q4 		$632K Sell
2,179
-2,442
-53% -$239K 0.01% 1130
2022
Q3 		$300K Sell
4,621
-719
-13% -$50K ﹤0.01% 2233
2022
Q2 		$382K Buy
+5,340
New +$393K 0.01% 1597
2021
Q3 		– Sell
-2,815
Closed -$274K – 2156
2021
Q2 		$274K Buy
+2,815
New +$333K ﹤0.01% 1386
2020
Q1 		– Sell
-2,410
Closed -$220K – 870
2019
Q4 		$220K Sell
2,410
-508
-17% -$49.3K ﹤0.01% 939
2019
Q3 		$252K Buy
+2,918
New +$274K 0.01% 867
2018
Q4 		– Sell
-1,839
Closed -$394K – 1088
2018
Q3 		$394K Buy
+1,839
New +$461K 0.01% 928
2015
Q3 		– Sell
-807
Closed -$63K – 647
2015
Q2 		$63K Buy
+807
New +$67.7K 0.01% 578
2015
Q1 		– Sell
-350
Closed -$33K – 458
2014
Q4 		$33K Sell
350
-215
-38% -$22.2K 0.01% 331
2014
Q3 		$60K Buy
+565
New +$78.6K 0.01% 669
2013
Q3 		– Sell
-316
Closed -$55K – 636
2013
Q2 		$55K Buy
+316
New +$82.4K 0.01% 546

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Verition Fund Management's MDGL Position: Q2 2026 in Review

Verition Fund Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 7,490 shares worth $4.02M. The stake represents 0.02% of the portfolio and ranks #754 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in MDGL as recently as Q4 2025.

Verition Fund Management first reported a position in MDGL in Q2 2013 and has held it in 24 quarters since. The position peaked at $5.18M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Verition Fund Management held 7,490 shares of Madrigal Pharmaceuticals worth $4.02M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Verition Fund Management position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.02% of Verition Fund Management's portfolio in Q2 2026, its #754 holding.
  • Verition Fund Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • Verition Fund Management's Madrigal Pharmaceuticals position peaked at $5.18M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.